A Safety Study of Autologous T Cells Engineered to Target CD19 and CRISPR Gene Edited to Eliminate Endogenous HPK1 (XYF19 CAR-T Cells) for Relapsed or Refractory Haematopoietic Malignancies.
The XYF19 CAR-T cell therapy, targeting CD19 and utilizing CRISPR technology to eliminate endogenous HPK1, represents a novel approach in treating relapsed or refractory CD19+ hematological malignancies, specifically B cell acute lymphoblastic leukemia (B-ALL) and various B cell lymphomas. Given the increasing demand for effective therapies in this patient population, the asset has significant commercial potential. The competitive landscape includes established CAR-T therapies such as Kymriah and Yescarta, which have demonstrated efficacy but also face challenges related to safety and accessibility. The unique mechanism of action and the focus on a specific patient subset may provide a differentiated value proposition. However, the trial's single-center design and early-phase status necessitate careful monitoring of recruitment and safety outcomes to ensure viability for future development and potential market entry.
Indication: Leukemia Lymphocytic Acute (ALL) in Relapse
Modality: cell therapy
Target: CD19 and endogenous HPK1 (CRISPR gene edited)
Sponsor: Xijing Hospital
Source URL: ClinicalTrials.gov
Source updated: Jul 30, 2019
Ingested: Jun 12, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD19 and endogenous HPK1 (CRISPR gene edited)
View original source fields
Condition raw: Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive
Condition normalized: Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD19 and endogenous HPK1 (CRISPR gene edited)
Target normalized: CD19 and endogenous HPK1 (CRISPR gene edited)